Testosterone Lawsuit News: JPML Holds Hearing on Possible Consolidation of Low Testosterone Therapy Claims

Share Article

The Firm is investigating testosterone treatment lawsuits on behalf of men who allegedly suffered heart attacks, strokes and other serious heart injuries due to low testosterone therapies.

Free Case Review
We have heard from numerous men who allegedly suffered serious cardiovascular events due to the use of low testosterone therapies.

As testosterone lawsuits (http://www.injurybeacon.com/testosterone-androgel/) continue to mount in courts around the country, Bernstein Liebhard LLP notes that the U.S. Judicial Panel on Multidistrict Litigation (JPML) heard oral arguments earlier today on a motion to establish a multisditrict litigation for all federally-filed product liability claims involving low testosterone therapies. If the JPML grants the motion, these lawsuits would be transferred to a single federal jurisdiction for coordinated pretrial proceedings. (In Re: AndroGel Product Liability Litigation, No. 2545, JPML)

“We have heard from numerous men who allegedly suffered serious cardiovascular events due to the use of low testosterone therapies. Our Firm is looking forwrd to the Panel's decision” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free and confidential case reviews to individuals who may have suffered heart attacks, strokes, deep vein thrombosis or pulmonary embolism due to their use of testosterone treatment therapies.

Testosterone Treatment Lawsuits

Prescription testosterone therapies are approved to treat low testosterone in men who suffer from the condition due to an underlying medical issue. Other medications in this class include:**

  •     Axiron
  •     AndroDerm
  •     AndroGel
  •     Bio-T Gel
  •     Delatestryl
  •     Depo-Testosterone
  •     Foresta
  •     Striant
  •     Testopel
  •     Testim

On January 31, 2014, the FDA announced that it was reviewing the heart risks that may be associated with prescription testosterone therapies after two studies found a high rate of heart attacks, strokes and death in men with preexisting heart problems who received testosterone.

Court documents indicate that more than 80 testosterone lawsuits have been filed in U.S. courts over serious cardiovascular injuries that were allegedly caused by medications in this class. The motion under consideration by the JPMPL intially requested the consolidation of all federally-filed AndroGel lawsuits. Hovever, the manufacturers of AndroGel, Axiron and Fortesta have filed briefs in support of the establishment of a multidistrict litigation, but have requested that the proceeding include all federal testosterone claims, regardless of the drugs involved.

Men who may have suffered strokes, heart attacks, deep vein thrombosis, pulmonary embolism or another serious cardiovascular event after using a low testosterone therapy may be eligible to file a lawsuit seeking compensation from its manufacturer. Learn more about filing a testosterone treatment lawsuit by calling our Firm today at 800-511-5092.

*accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&searchTerm=testosterone&Search_Button=Submit, FDA

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website